REGENXBIO Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $170.4M | $83.3M | $90.2M | $112.7M | $470.3M |
| Operating income | -$161.2M | -$233.3M | -$268.1M | -$262.9M | $160.0M |
| Cost of revenue | — | $33.6M | $37.2M | $54.5M | $51.8M |
| Cash from operations | -$124.0M | -$173.1M | -$218.4M | -$207.5M | $218.9M |
| Capital expenditure | $2.4M | $2.4M | $10.0M | $30.7M | $84.2M |
| Free cash flow | -$126.4M | -$175.6M | -$228.4M | -$238.2M | $134.7M |
| Impairments | — | $2.1M | $0 | $0 | $0 |
| Total assets | $453.0M | $466.0M | $574.0M | $833.3M | $1.1B |
| Total liabilities | $350.3M | $206.3M | $262.2M | $317.1M | $349.6M |
Shares outstanding 51.7M · Free float 72.4%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.